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Heart failure is characterized by a debilitating decline in cardiac function 1 , and recent clinical trial results indicate that improving the contractility of heart muscle cells by boosting intracellular calcium handling might be an effective therapy 2, 3 . MicroRNAs (miRNAs) are dysregulated in heart failure 4, 5 but whether they control contractility or constitute therapeutic targets remains speculative. Using high-throughput functional screening of the human microRNAome, here we identify miRNAs that suppress intracellular calcium handling in heart muscle by interacting with messenger RNA encoding the sarcoplasmic reticulum calcium uptake pump SERCA2a (also known as ATP2A2). Of 875 miRNAs tested, miR-25 potently delayed calcium uptake kinetics in cardiomyocytes in vitro and was upregulated in heart failure, both in mice and humans. Whereas adenoassociated virus 9 (AAV9)-mediated overexpression of miR-25 in vivo resulted in a significant loss of contractile function, injection of an antisense oligonucleotide (antagomiR) against miR-25 markedly halted established heart failure in a mouse model, improving cardiac function and survival relative to a control antagomiR oligonucleotide. These data reveal that increased expression of endogenous miR-25 contributes to declining cardiac function during heart failure and suggest that it might be targeted therapeutically to restore function.
Heart failure is the culmination of diverse cardiovascular diseases, including hypertension, ischaemic disease and atherosclerosis, valvular insufficiency, myocarditis, and contractile protein mutations, and is uniformly characterized by a progressive loss of contractile function and reserve 1 . The prevailing therapeutic strategy is to block the deleterious effects of the renin-angiotensin and sympathetic systems, but existing drugs target few mechanisms within the failing cardiomyocyte and there is a critical need for novel drugs, especially for treating patients with advanced heart failure 6, 7 . A complex intracellular network balances contractility and intracellular Ca 21 handling in relation to workload 8 ; however, the role of miRNAs in cardiac contractility remains largely unexplored. miRNAs fine tune nearly all normal and pathological processes by downregulating proteins that occupy key nodal points in biological control networks 9, 10 . We reasoned that miRNAs that repress contractility 11 might be upregulated during human heart failure, and might therefore constitute novel targets for therapeutic intervention.
The calcium-transporting ATPase SERCA2a is the primary mechanism of Ca 21 uptake during excitation-contraction coupling in cardiomyocytes. Impaired Ca 21 uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure 2 . Accordingly, restoration of SERCA2a by gene transfer has proven effective in improving key parameters of heart failure in animal models 12 and more recently in clinical trials 3 . Thus, miRNAs that downregulate SERCA2a might be elevated in heart failure and compromise cardiac function. Computational algorithms predict .300 miRNAs that target SERCA2a (miRNA Data Integration Portal 13 ), but they are error prone, necessitating empirical evaluation 14 . We therefore functionally screened a wholegenome collection of miRNAs for selective downregulation of the Ca 21 pump. To perform the screen, we fused the SERCA2a mRNA 39 untranslated region (UTR) sequence downstream of an enhanced green fluorescent protein (eGFP) coding region, making a 'target sensor' construct to permit detection of active miRNAs by a decrease in eGFP fluorescence ( Fig. 1a, b) . In the primary screen, 144 miRNAs reduced eGFP fluorescence by .30% with P , 0.05 ( Fig. 1c, d) , and 82 were confirmed by testing through a dose range (Fig. 1e, f and Supplementary Table 1 ). Thirty-two were evolutionarily conserved and 15 were both evolutionarily conserved and reported to be upregulated in human heart failure (see Methods) ( Fig. 1e ). Four caused a highly significant (P , 0.001, one-tailed analysis of variance (ANOVA)) prolongation of the decay phase of the Ca 21 transient in the cardiomyocyte HL-1 cell line, shown here as the duration from 75% to 25% maximal value, CaTD 75-25 ( Fig. 1g) , measured using an automated platform 15 . The most potent miRNA was miR-25, which elicited a physiological effect comparable to that of the short interfering RNA (siRNA) directed against SERCA2a, siSERCA2a ( Fig. 1h ). We confirmed that miR-25 is upregulated in human myocardial samples from patients with severe heart failure ( Fig. 1i ). In situ hybridization revealed that miR-25 is expressed primarily in cardiomyocytes of trans-aortic constriction (TAC)-induced failing mouse hearts, with no detectable expression in cardiac fibroblasts or vascular endothelial cells, and low expression in vascular smooth muscle ( Fig. 2) .
To establish a link between miR-25 and cardiac function, we identified putative protein targets involved in Ca 21 handling computationally (DianaLab miRPath with TargetScan Mouse v.5.0, see Methods). In addition to SERCA2a, these included inositol-1,4,5-trisphosphate receptor 1 (IP3R1), which was selectively downregulated by miR-25 transient transfection in HL-1 cells ( Fig. 3a and Extended Data Fig. 1a ). Other candidate proteins involved in calcium handling, including the sodium-calcium exchanger (NCX1; also known as SLC8A1), calmodulin kinase 2 (CaMKII), phospholamban (PLN) and calmodulin 3 (CALM3) were unaffected in HL-1 cells transfected with miR-25 (Extended Data Fig. 2 ). miRNAs bind cognate mRNAs by imprecise base pairing to specific recognition elements 9, 10 . Single putative miR-25 recognition sites were identified within SERCA2a and IP3R1 39 UTR sequences by TargetScan Human v.6.2 ( Fig. 3b and Extended Data Fig. 1b ). Mutation of these sequences abolished the ability of miR-25 to inhibit reporter expression ( Fig. 3b and Extended Data Fig. 1b ), further supporting selective miR-25 interactions with the mRNAs, and indicating that the single recognition elements identified in the 39 UTRs of the SERCA2a and IP3R1 mRNAs are sufficient for miR-25 activity.
Having shown that miR-25 regulates SERCA2a and IP3R1, we evaluated whether siRNAs directed against these proteins could mimic the effect of miR-25 on cardiac Ca 21 transient kinetics in vitro. Transfection of siSerca2a significantly slowed the decay (Ca 21 re-uptake) phase of the transient (CaTD 75-25 ) relative to controls in spontaneously contracting HL-1 cells ( Fig. 3c and Extended Data Fig. 1c ) and neonatal rat ventricular cardiomyocytes (NRVCs; Extended Data Fig. 1d ); however, the maximal velocity of the upstroke phase of the Ca 21 transient (V max ) was unchanged (Extended Data Fig. 3 ), accurately reproducing the effect of miR-25 and mimicking the ,1.5-2-fold decline reported for ventricular cardiomyocytes isolated from failing human hearts 16, 17 . siRNA against IP3R1 only minimally affected Ca 21 transient kinetics in HL-1 cells and not at all in NRVCs (CaTD 50 , CaTD 75-25 and V max ; Fig. 3c and Extended Data Fig. 3 ), suggesting that the predominant effect of miR-25 on Ca 21 transient kinetics is mediated through downregulation of SERCA2a.
We evaluated the physiological effect of blocking miR-25. AntagomiRs are antisense oligonucleotides modified to enhance duplex stability and have been used effectively to inhibit miRNA function in vitro and in vivo 18 . Anti-miR-25 transfection alone decreased CaTD 75-25 in HL-1 cells but had no effect in NRVCs ( Fig. 3c and Extended Data Fig. 1d ). Importantly, when co-transfected, anti-miR-25 cancelled the prolonging effect of miR-25 on CaTD 75-25 , restoring kinetic parameters to near normal in both cell types.
We next assessed the physiological consequences of administering miR-25 and anti-miR-25 in vivo. AAV9-mediated gene transfer of miR-25 increased the levels of miR-25 by approximately 50% and correspondingly decreased SERCA2a levels in ventricular myocardium ( Fig. 3d-f ), causing a progressive decline in fractional shortening, an index of cardiac function ( Fig. 3g, h) . Haemodynamic analyses at the termination of the studies (6 weeks after AAV transfer) confirmed that left ventricular (LV) function had declined in miR-25-injected mice ( Fig. 3i -k and Extended Data Fig. 4b, c ). By contrast, AAV-mediated transfer of miR-92a ( Fig. 3d, e ), which has the same seed sequence (AUUGCAC) as miR-25, did not affect SERCA2a levels ( Fig. 3f ) or significantly affect LV function ( Fig. 3g -k and Extended Data Fig. 4b , c), although it downregulated integrin a5, a target involved in angiogenesis 19 (Extended Data Fig. 4a ), despite the identical copy number of integrated AAV genomes (Extended Data Fig. 5 ). Together, these results point to a selective interaction between miR-25 and Serca2a mRNA that is consistent with the importance of non-seed sequences for target specificity 20 
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evaluate the selectivity and efficacy of anti-miR-25, we intravenously injected anti-miRNAs formulated with in vivo-jetPEI reagent mixture. Anti-miR-25 injection decreased endogenous miR-25 levels in LV myocardium of both wild-type and SERCA2a knockout mice relative to treatment with a control (scrambled sequence) anti-miR (Extended Data Fig. 6a ), but did not affect miR-92a (Extended Data Fig. 7 ). Accordingly, anti-miR-25 increased SERCA2a levels as expected in wild-type mice (Extended Data Fig. 6b ). Notably, however, anti-miR-25 did not improve the cardiac morphometric or haemodynamic parameters of SERCA2a knockout mice (Extended Data Fig. 8 ), suggesting that the Ca 21 pump is a critical target for miR-25.
Because miR-25 decreased SERCA2a levels in vitro and in vivo, we evaluated whether administration of anti-miR-25 would affect cardiac function during chronic heart failure. Mice were subjected to 3 months of TAC to chronically increase LV load and cause LV dilation before administering anti-miR-25. Once heart failure was established, anti-miR-25 or a control anti-miRNA were injected intravenously and the mice were subsequently monitored for their effects on heart function ( Fig. 4a ). Echocardiography revealed substantial improvements in cardiac function after injection of anti-miR-25 at 4.5 and 5.5 months after TAC, despite constant pressure overload, compared with severe deterioration in animals injected with the control anti-miRNA (Fig. 4b, c and Supplementary Table 2 ). Furthermore, haemodynamic analyses at the termination of the studies (5.5 months after TAC) showed substantially improved LV function in the anti-miR-25-injected mice, with the treatment effectively restoring the load-independent parameter end systolic pressure volume relationship (ESPVR) and the ejection fraction (EF) to normal levels ( Fig. 4d-f and Supplementary Table 3 ). The heart weight to body weight ratio was also stabilized ( Fig. 4g ). Survival of the TAC-induced heart failure animals was also improved, with 7/8 anti-miR-25-injected and 8/8 sham-operated animals surviving versus 7/22 of the control anti-miRNA-injected animals (Kaplan-Meier analysis, Extended Data Fig. 9 ), reflected by an increased probability of survival of TAC animals injected with anti-miR-25 versus control anti-miRNA (P 5 0.0131, log-rank test). Consistent with improved cardiac function, anti-miR-25-injected mice had significantly reduced levels of endogenous miR-25 compared with control animals (both TAC (Fig. 4h ) and sham-operated (Extended Data Fig. 6a) ). Neither anti-miR-25 nor the control anti-miRNA affected the cardiac physiology of sham-operated animals (Extended Data Fig. 8 ). Total and SUMOylated SERCA2a levels were significantly increased ( Fig. 4i and Extended Data Fig. 10 ), indicating that anti-miR-25 injection restored the loss of SERCA2a protein as well as post-translational modifications of SERCA2a such as SUMOylation (which improves transporter stability and ATPase activity 21 ) despite the prior onset of heart failure. Furthermore, injection of anti-miR-25 reduced fibrosis ( Fig. 4j -l, n-p, r-t, v) and also normalized cardiomyocyte cell size ( Fig. 4m , q, u, w). Given that anti-miR-25 had no salutary effect on cardiac morphometric or haemodynamic parameters in SERCA2a knockout mice (Extended Data Fig. 8 ), did not affect expression of other miRNAs with homologous seed sequences (Extended Data Fig. 7) , and that AAV9-mediated cardiac transfer of miR-25 selectively affected SERCA2a (Fig. 3f ), we propose that the 
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beneficial effect of anti-miR-25 is due to the inhibition of pathologically upregulated endogenous miR-25 and the subsequent restoration of SERCA2a activity. To our knowledge, these data provide the first evidence that cardiac delivery of an anti-miRNA can directly control SERCA2a protein levels to achieve a long-term improvement in cardiac function. These studies identified miR-25 as a critical repressor of SERCA2a and cardiac function during heart failure. Of note, several mechanisms beyond SERCA2a deficiency, such as changes in K 1 channel density, NCX expression and myofilament sensitivity to Ca 21 , also contribute to slowing of the Ca 21 transient in advanced heart failure 22 . miR-25 might also control IP3R1, and thus could be involved under conditions of inositol-1,4,5-trisphosphate sensitization, such as in response to endothelin 1, angiotensin and phenylephrine 23 or in local Ca 21 control 24 . NADPH oxidase 4 (NOX4) was recently shown to be downregulated 
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by miR-25 in a mouse model of diabetic nephropathy 25 ; however, NOX4 levels did not change significantly in our long-term TAC heart failure model (data not shown). Whether NOX4, which is responsible for the production of superoxide, might contribute to the salutary effects of anti-miR-25 therapy is unclear as it is reported to confer both protective and detrimental effects 26 . Finally, miR-25 was recently reported to decrease acutely after aortic constriction in mice 27 , in contrast with the chronic elevation reported here and in human heart failure samples, perhaps reflecting the very different stages of pathogenesis. In conclusion, our data suggest that inhibition of miR-25 may be a novel therapeutic strategy for the treatment of heart failure.
METHODS SUMMARY
For primary screening, HEK293 cells were co-transfected with the Ambion Pre-miR miRNA Precursor Human v.2.0 microRNA library (25 nM) and 300 ng SERCA2a 39 UTR target sensor plasmid (Fig. 1a) per well in 384-well plates, in triplicate. For secondary screening, Ca 21 transient recordings (10 s, 33 frames per second) were acquired from HL-1 cardiomyocytes and NRVCs transfected with candidate miRNAs and loaded with Hoechst 33342 and Fluo-4 72 h after transfection, and analysed to derive cytoplasmic calcium transient kinetic parameters using a KIC instrument and software (Vala Sciences). Unresponsive or low responding cells were removed by gating. Statistical significance was determined using one-way ANOVA.
All mice were housed and treated in accordance with guidelines from the National Institutes of Health and institutional animal care and use committees, and protocols were approved by the Mount Sinai School of Medicine or Sanford-Burnham Medical Research Institute animal care and use committees.
LV samples were from explanted hearts of patients with severe heart failure, obtained at the time of cardiac transplantation. Non-failing hearts (controls) were from patients who died of cerebrovascular accidents with no evidence of contractile dysfunction by echocardiography. The 5 non-failing hearts (3 males and 2 females) had a median age of 43. The 5 heart-failure patients (4 males and 1 female) had a median age of 54 and their mean EF before cardiac transplantation was 22 6 3%.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell culture. HEK293 cells were maintained in DMEM/F12 medium supplemented with 10% FBS, 100 units ml 21 penicillin and 100 mg ml 21 streptomycin. HL-1 cells were maintained in Claycomb medium (Sigma) supplemented with 10% FBS (Sigma), 100 units ml 21 penicillin, 100 mg ml 21 streptomycin, 2 mM L-glutamine, 0.1 mM noradrenaline (Sigma) and passaged approximately every 3-4 days when cells reached confluency and spontaneous contractions were observed. For transient transfection of both cell lines, Lipofectamine 2000 (Life Technologies) was used following the manufacturer's protocol. Cy3-labelled negative control siRNA (Ambion, AM4621) or miRNA (Ambion, AM17120) was used for control in all transfection experiments. Transfection efficiency was .90%.
NRVCs were isolated with the neonatal rat cardiomyocyte isolation kit (Worthington) and cultured at 37 uC with 5% CO 2 . In brief, ventricles were dissected from 1-2-day-old Hsd:Sprague-Dawley rats, then digested overnight at 4 uC with trypsin. Digestion continued the following morning with collagenase for approximately 90 min at 37 uC. Cells were pooled, pre-plated for 90 min on an uncoated dish to remove fibroblasts, and transfected as above on matrigel-coated cell culture plastic dishes in high-serum media (DMEM/F12 (1:1), 0.2% BSA, 3 mM sodium-pyruvate, 0.1 mM ascorbic acid, 4 mg l 21 transferrin, 2 mM L-glutamine, 100 nM thyroid hormone (T3) supplemented with 10% horse serum and 5% FCS) at 2 3 10 5 cells cm 22 . After 24 h, media was changed to low-serum medium (the same but with 0.25% FCS). At 72 h cells were processed for calcium imaging (see later). Target sensor. To screen for miRNA repression of the cardiac-specific SERCA2a isoform we substituted the CMV promoter of the pDsRed-N1 vector (Clontech) with the hPGK promoter driving expression of eGFP. We focused on the SERCA2a 39 UTR as it is selectively expressed in cardiomyocytes (in contrast to SERCA2b sequences) to test the hypothesis that the cardiac-specific isoform might be under distinct regulatory control. DsRed sequence was replaced with the human SERCA2a 39 UTR sequence (nucleotides 3503-4302, GenBank accession number NM_001681.3), which was obtained by PCR of differentiated human embryonic stem cells displaying spontaneous contractions. Primer sequences used for amplification were as follows: human SERCA2a forward: 59-CGGGGTACCTGCAATACTGGAGTA ACCGCTTC-39; human SERCA2a reverse: 59-CGGCGGCCGCATTTACCTGA AACCATGTCTGTGC-39. miRNA screen. HEK293 cells were co-transfected with the Ambion Pre-miR miRNA Precursor Human v.2.0 microRNA library and 300 ng SERCA2a 39 UTR target sensor plasmid per well in 384-well plates (Greiner). Transfections were performed using Lipofectamine 2000 (Life Technologies) in triplicate with 25 nM of each miRNA. At 48 h after transfection cells were fixed in 4% paraformaldehyde and imaging was performed using an automated fluorescent microscope (InCell Analyzer 1000; GE Healthcare) and analysed using CyteSeer software (Vala Sciences) by quantifying Total Integrated Pixel Intensity within an eGFP-positive area, as described 28, 29 . Hits were confirmed by a 5-point dose response assay (50 nM to 3.125 nM), and data plotted (Fig. 1e ) as the AUC. Thirty-two were determined to be evolutionarily conserved between mouse and human (TargetScan v.6.2), and 15 were both evolutionarily conserved and reported to be upregulated in human heart failure 4, 5, [30] [31] [32] [33] [34] [35] [36] . Site-directed mutagenesis. Site-directed mutagenesis was used to modify the miR-25 seed binding sequence using Pfu Turbo DNA Polymerase. DpnI was used to digest non-mutated DNA template before transforming the mutated plasmids. Primers used were as follows: SERCA2a 39 UTR forward: 59-GCAGTAGACAGATGTTG TTCGAATACAAATATTGTGATGC-39; SERCA2a 39 UTR reverse: 59-GCATC ACAATATTTGTATTCGAACAACATGTGTCTACTGC-39; IP3R1 39 UTR forward: 59-ATGTTTTTTATAAAACTCATATGTACGAATTATGCAATCAC-39; IP3R1 39 UTR reverse: 59-GTGATTGCATAATTCGTACATATGAGTTTTATA AAAAACAT-39.
The mutated sequences were designed to contain restriction enzyme recognition sites (highlighted in bold), used to verify correct mutation of the seed site. IP3R1 target sensor luciferase assay. HEK293 cells were co-transfected with miRNA (25 nM) and 100 ng human IP3R Type 1 miTarget (GeneCopoeia). Fortyeight hours after transfection, reporter activity was analysed using the Dual-Glo Luciferase Assay System (Promega) and EnVision plate reader (PerkinElmer). Data are presented as a ratio of firefly luciferase activity normalized to Renilla luciferase. RT-qPCR. RNA was isolated from human tissue using Trizol (Life Technologies) according to the manufacturer's protocol. All-in-One miRNA qRT-PCR Detection Kit (GeneCopoeia) was used for both cDNA synthesis and quantitative detection using miR-25-specific primers (GeneCopoeia). Rnu6 was used for normalization.
RNA was isolated from mouse tissue using mirVana miRNA Isolation kit (Life Technologies) according to the manufacturer's protocol. The TaqMan MicroRNA Assays kit (Life Technologies) was used for both cDNA synthesis and qPCR using miR-25 primers (Life Technologies). miR-24 was used for normalization. In situ hybridization. To characterize the distribution and cellular origin of miR-25 in heart failure we performed in situ hybridization on 10 mm-thick cryosections of TAC-induced heart failure mice (1 month post-TAC). Sections were fixed by 4% paraformaldehyde for 10 min, acetylated for 10 min and permeabilized for 5 min by proteinase K treatment (5 m ml 21 ). Prehybridization of sections was performed for 4 h at RNA melting temperature (T m ) minus 30 uC (specific for each LNA probe) before overnight hybridization with 25 nM 59-DIG-and 39-DIGlabelled miRCURY LNA miRNA detection probes (Exiqon) for miR-25 (18122-15), negative control miR-159 (99003-15) and positive control U6 (99002-15) at T m minus 30 uC in denaturizing hybridization buffer. To remove unbound and partially bound probes slides were washed for 15 min in 53 SSC and for 1 h in 0.23 SSC at 60 uC. After washing, sections were blocked for 1 h before overnight incubation at 4 uC with anti-DIG alkaline phosphatase antibody (1:1,500, Roche) . For miRNA visualization, sections were subsequently incubated in Liquid Permanent Red (Dako) for 6 h. Co-staining for the non-cardiomyocyte fraction was performed by incubation with lectin BS-1 (1:100, Sigma) , anti-a-SMA (1:400, Sigma), or periostin (1:50, Sigma) for 1 h at room temperature (22 uC), followed by 1 h incubation with appropriate Alexa Fluor 488 secondary antibodies (Life Technologies). Hoechst 33342 (Life Technologies) was used as a counterstain and slides were mounted in Fluoromount G (SouthernBiotech). Images were captured using cellP software (Olympus) on an Olympus BX60 microscope and processed with Adobe Photoshop Cs4 v.11. Protein expression analyses. For in vitro transfection experiments using HL-1 cells, cells were transfected with miRNAs (50 nM), and samples were lysed 72 h later using Novex Tris-Glycine 23 Sample Buffer supplemented with 5% b-mercaptoethanol at 55 uC for 1 h. Samples were loaded on SDS-PAGE gels for separation, followed by blotting of protein onto polyvinylidene fluoride membrane. Membranes were then incubated as follows: SERCA2a (1:2,000; 21st Century Biochemicals), IP3R1 (1:200, goat polyclonal, sc-6093; Santa Cruz Biotechnology), calmodulin (1:2,000, rabbit monoclonal, ab45689; Abcam), NCX1 (1:500, mouse monoclonal, MAB1590; Chemicon), GAPDH (1:1,000, rabbit polyclonoal, ab9485; Abcam), phosopholamban (1:500, mouse monoclonal, 05-205; Upstate) and CaMKII (1:10,000, gift from J. H. Brown laboratory). AlexaFluor-labelled secondary antibodies were used (1:10,000) for detection of the specific bands. Quantitative analysis was done using the Odyssey imaging system (LI-COR Biosciences). Calcium imaging and analysis. HL-1 cells were seeded at a density of 25,000 cells per well on 96-well glass-bottom plates (Greiner) and transfected with 50 nM miRNAs as described for cell culture earlier. NRVCs were seeded at a density of 60,000 cells per well, and were processed identically, with the addition of a single 15 V electrical pulse of 5 ms at 1 Hz, initiated at 2 s into recording.
Seventy-two hours after transfection, cells were loaded with 200 ng ml 21 Hoechst 33342 (Sigma) and Fluo-4 for 30 min at 37 uC followed by 30 min at room temperature. Fluo-4 NW Calcium Assay Kit (Life Technologies) was prepared according to the manufacturer's instructions in 13 Hanks Balanced Salt Solution containing 20 mM HEPES buffer (Life Technologies) and 2.5 mM Probenecid (Life Technologies). After loading, cells were incubated with Tyrode's solution (140 mM NaCl, 6 mM KCl, 1 mM MgCl 2 , 5mM HEPES, 2 mM CaCl 2 , 10mM glucose, pH 7.4) for imaging. Ca 21 transient recordings were done using a Kinetic Image Cytometer IC 100 (Vala Sciences). Video streams of 10 s of the Fluo-4 green channel were collected for each well at 33 frames per second. Autofocus by the IC 100 was performed automatically by video acquisition using the nuclear channel. All image capture was performed with a 320 0.50 numerical aperture (NA) objective. Cytometric calcium kinetic parameters were determined by image analysis using CyteSeer software (Vala Sciences) and unresponsive or low responding cells were removed by gating. Bioinformatics. Predicted miR-25 target binding sites were obtained from TargetScan Human v.6.2 (http://www.targetscan.org). Potential targets of miR-25 involved in calcium signalling pathways were identified using DianaLab miRPath with Target-Scan Mouse v.5.0 prediction software (http://diana.cslab.ece.ntua.gr/pathways). AAV9 transduction. AAV9-miR-25 and AAV9-miR-92a were produced using the two-plasmids protocol described previously 37 with the following modifications: 293-T cells (ATCC) were grown in triple flasks for 24 h (DMEM, 10% FBS) before the transfection using polyethyleneimine (PEI). After 72 h, cells were harvested and only DNase resistant virus was purified by an iodixanol density gradient (Optiprep; Greiner Bio-One). Finally, viruses were concentrated and formulated into lactated Ringer's solution (Baxter Healthcare Corporation) using a Vivaspin 20 Centrifugal concentrator 100K MWCO (Vivascience) and stored at 280 uC. On the day of the injection, mice were immobilized using the single mouse restrainer (Harvard apparatus) and the indicated amount (5 3 10 11 vector genomes (vg) per mouse) of AAV9 was injected through the tail vein.
AAV transduction of miR-25 and miR-92a yielded a comparable copy number (Extended Data Fig. 5 ). To quantify miR-25 and miR-92a copy number in mice, we used a SYBR green-based real-time quantitative assay. Genomic AAV9-miR-25 and miR-92a vector DNA was extracted from frozen cardiac tissues by using DNeasy Tissue Kits (Qiagen). The real-time qPCR assay detects a 145-bp sequence RESEARCH LETTER unique to the SV40 promoter in the AAV9 vector (forward: TTGGACAAACCA CAACTAGAA; reverse: AACCTCCCACACCTCCC). Genomic DNA was isolated from the indicated tissues and 100 ng of each sample was used in duplicate to determine vector genome copies. The plasmid DNA was used as a copy number standard ranging from 10 to 10 8 copies ml 21 . The lower limit detection of the assay was 150 copies mg 21 DNA. TAC surgery. Male mice (B6C3F1 strain) of 8-10 weeks of age (25-30 g) were used. The animals were anaesthetized with ketamine (95 mg kg 21 ) and xylazine (5 mg kg 21 ) administered via intraperitoneal injection. The mice were ventilated with a tidal volume of 0.1 ml and a respiratory rate of 110 breaths per minute (Harvard Apparatus). A longitudinal incision of 2-3 mm was made in the proximal sternum to allow visualization of the aortic arch. The transverse aortic arch was ligated between the innominate and left common carotid arteries with an overlaid 27-gauge needle. The needle was then immediately removed, leaving a discrete region of constriction. Echocardiography was performed and Doppler was used to calculate the pressure gradient between proximal and distal sites of the transverse aortic constriction. Only animals with a pressure gradient .30 mm Hg were included in this study. After 8 weeks, additional echocardiography was performed to evaluate cardiac function. Only animals with FS , 50% were determined as being in heart failure and suitable for further study. Anti-miRNA administration. Anti-miR-25 (product code AM10584), anti-miRNA negative control (product code AM17010) were purchased from Ambion. Separate solutions of anti-miR-25 and anti-miRNA negative control were each diluted with in vivo-jetPEI solution (catalogue no. 201-50, Polyplus-transfection) containing 10% (wt/vol) glucose at a ratio of in vivo-jetPEI nitrogen residues per oligonucleotide phosphate of 5, following the recommendations of the manufacturer. All solutions were mixed by vortexing for 10 s and incubated for at least 15 min at 37 uC before injection. Each mouse received 400 ml saline and oligonucleotide mixture (100 ml of oligonucleotide solution plus 300 ml of saline, corresponding to 300 mg of oligonucleotide per dose) through tail vein injection consecutively for 3 days and 3 additional injections were performed once a week for the following 3 weeks. Two additional groups of control animals were included: one consisting of untreated animals and the other of animals receiving a mixture of in vivo-jetPEI solution containing 10% (wt/vol) glucose without added oligonucleotide. All injections were carried out using a 30-gauge needle syringe with single mouse restrainer (Harvard apparatus). Production of SERCA2a knockout mice. Conditional SERCA2 knockout mice were donated by G. Christensen 38 . The mice were generated by standard gene targeting strategies to introduce loxP sites into introns 1 and 3 of the Serca2. For our studies, 8-10-week-old mice were injected intraperitoneally with 4-OHtamoxifen (1 mg per day) for 4 days to induce cardiomyocyte-specific excision of the Serca2 gene sequences, essentially as described 38, 39 . Echocardiography and in vivo haemodynamics. B6C3F1 mice were acquired from Jackson laboratories. Mice were anaesthetized with intraperitoneal ketamine (100 mg g 21 ) for echocardiographic analysis. Two-dimensional images and M-mode tracings were recorded on the short-axis at the level of the papillary muscle to determine percent fractional shortening and ventricular dimensions (GE Vivid Vision). One day after echocardiography, in vivo haemodynamics were performed using a 1.2 Fr pressure-volume (PV) conductance catheter (Scisense). Mice were anaesthetized with an intraperitoneal injection mixture of urethane (1 mg g 21 ), etomidate (10 mg g 21 ) and morphine (1 mg g 21 ) and were then intubated via a tracheotomy and mechanically ventilated at 7 ml g 21 tidal volume and 120 respirations per minute. The PV catheter was placed in the LV via an apical stab approach as previously described 40 . Pressure-volume data were analysed using IOX2 software (EMKA technologies). All procedures were approved by and performed in accordance with the Institutional Animal Care and Use Committee of the Mount Sinai School of Medicine. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996). Histological examination of cardiac tissues. To measure cardiomyocyte crosssectional area, suitable cross-sections with nearly circular capillary profiles and nuclei were selected on sections stained with WGA followed by a fluorescein isothiocyanate (FITC)-conjugated rabbit polyclonal to WGA (1:100; ab20528, Abcam). These were observed using an Axiophot microscope (Carl Zeiss), and then analysed using the Analysis-SIS3.2 software (Soft-Imaging System). To measure the fibrotic areas, a Masson-trichrome staining kit (Sigma-Aldrich; HT15-1kt) was used for staining of the sectioned hearts. The fibrotic areas stained blue and the normal tissue stained red. The fibrotic area was calculated as the ratio of the total area of fibrosis to the total area of the section. Statistical analysis. Data are presented as mean 6 s.e.m.. Unpaired Student's t-test or ANOVA was performed as indicated to determine statistical differences. Whisker box plots show outliers beyond the 5th and 95th percentiles. All statistical analyses were done using GraphPad Prism software. with that of siRNAs against SERCA2a and IP3R isoforms. Cardiomyocytelike HL-1 cells were transfected with miR-25, siRNA to SERCA2a (siSerca2a) (left panels) or siRNAs to IP3R1 or IP3R2 (siIP3R1, siIP3R2) (right panels), and analysed 72 h later by kinetic imaging cytometry. Kinetic parameters are CaTD 50 , CaTD 75-25 and V max upstroke. Data are represented as whisker plots, with the box denoting the 25th and 75th percentiles, the whiskers the 5th and 95th percentiles, the middle bar the median, and outliers indicated as individual dots. Note that siSerca2a and miR-25 elicited comparable effects, both markedly delaying the Ca 21 uptake phase parameters CaTD 50 and CaTD 75-25 without appreciably altering the V max upstroke kinetics (n . 550 cells per group). Box defines interquartile range; whiskers indicate 6 5th and 95th percentile; dots indicate outliers. Also note that siIP3R1 only minimally affected the Ca 21 kinetic parameters. siIP3R2 slowed V max upstroke and broadened the distribution of uptake phase kinetic parameters CaTD 50 and CaTD 75-25 .
miR-25 in contrast slowed the uptake phase parameters but did not appreciably affect V max upstroke (n . 550 cells per group). Box defines interquartile range; whiskers indicate 6 5th and 95th percentile; dots indicate outliers. Although IP3R1 might be a direct target of miR-25, several lines of evidence suggest that it is unlikely to mediate the effect of miR-25 in heart failure. IP3Rs are intracellular ligand-gated Ca 21 release channels 41 that in the sarcoplasmic reticulum are associated with excitation-contraction coupling or spontaneous Ca 21 release and enhanced Ca 21 transients, whereas in the nuclear envelope they promote nuclear Ca 21 signalling [42] [43] [44] , but a specific role for IP3R1 in heart failure has not been identified. Nonetheless, the control of IP3R1 by miR-25 might have a critical role under conditions that sensitize cardiomyocytes to inositol-1,4,5-trisphosphate, such as in response to endothelin 1, angiotensin and phenylephrine 23 or in local Ca 21 control 24 . Experiments were replicated two times.
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